BiotechTube
Azad Pharma

Azad Pharma

Basel, Switzerland· Est.
azad.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Azad Pharma is a private, commercial-stage company in the generic pharmaceuticals sector, leveraging its expertise in chemistry and formulation to provide patent-circumventing APIs and finished dosage forms. With headquarters in Switzerland and operational offices in Armenia, Canada, and China, the company targets a broad international market. Its leadership, including a CEO with deep Johnson & Johnson experience, guides a business model centered on providing cost-effective alternatives to branded drugs post-patent expiry, positioning it within the essential but competitive global generics market.

Generic Drugs

Technology Platform

Expertise in developing non-infringing synthetic pathways for generic APIs and novel formulations for finished dosage forms, focusing on chemistry, process development, and regulatory compliance.

Funding History

3
Total raised:$75M
Series B$45M
Series A$22M
Seed$8M

Opportunities

The ongoing global wave of patent expiries for blockbuster drugs creates a steady stream of new targets for generic competition.
Growing demand for affordable medicines in emerging markets, where Azad has a presence, offers significant expansion potential.
The company's niche in developing complex, patent-circumventing processes positions it well for higher-margin opportunities within the generics space.

Risk Factors

The company faces significant litigation risk from originator companies defending their patents, which can be costly and delay product launches.
Intense price competition in the global generics market and potential regulatory actions due to compliance failures pose major threats to profitability and operations.
Geopolitical instability in regions where it operates (e.g., Armenia) could disrupt its supply chain and client support.

Competitive Landscape

Azad operates in the highly competitive global generic API and finished dose sector, competing against large multinational generics firms (e.g., Teva, Sandoz) and numerous low-cost manufacturers, particularly from India and China. Its differentiation lies in a focused strategy on complex, patent-challenging products rather than broad commodity generics, competing on technical expertise and regulatory agility rather than scale alone.

More companies in Small Molecule Drugs →More companies in Switzerland →